171 related articles for article (PubMed ID: 34432381)
1. Generating CRISPR-Cas9-Mediated Null Mutations and Screening Targeting Efficiency in Human Pluripotent Stem Cells.
Bower OJ; McCarthy A; Lea RA; Alanis-Lobato G; Zohren J; Gerri C; Turner JMA; Niakan KK
Curr Protoc; 2021 Aug; 1(8):e232. PubMed ID: 34432381
[TBL] [Abstract][Full Text] [Related]
2. Efficient Cas9-based Genome Editing Using CRISPR Analysis Webtools in Severe Early-onset-obesity Patient-derived iPSCs.
Patel A; Iannello G; Diaz AG; Sirabella D; Thaker V; Corneo B
Curr Protoc; 2022 Aug; 2(8):e519. PubMed ID: 35950852
[TBL] [Abstract][Full Text] [Related]
3. Efficient Multi-Allelic Genome Editing of Primary Cell Cultures via CRISPR-Cas9 Ribonucleoprotein Nucleofection.
Hoellerbauer P; Kufeld M; Paddison PJ
Curr Protoc Stem Cell Biol; 2020 Sep; 54(1):e126. PubMed ID: 32833346
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Protocols for CRISPR/Cas9-based Gene Editing in Human Pluripotent Stem Cells.
Santos DP; Kiskinis E; Eggan K; Merkle FT
Curr Protoc Stem Cell Biol; 2016 Aug; 38():5B.6.1-5B.6.60. PubMed ID: 27532820
[TBL] [Abstract][Full Text] [Related]
5. Highly Efficient CRISPR/Cas9-Mediated Genome Editing in Human Pluripotent Stem Cells.
Maguire JA; Gadue P; French DL
Curr Protoc; 2022 Nov; 2(11):e590. PubMed ID: 36426905
[TBL] [Abstract][Full Text] [Related]
6. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.
Ihry RJ; Worringer KA; Salick MR; Frias E; Ho D; Theriault K; Kommineni S; Chen J; Sondey M; Ye C; Randhawa R; Kulkarni T; Yang Z; McAllister G; Russ C; Reece-Hoyes J; Forrester W; Hoffman GR; Dolmetsch R; Kaykas A
Nat Med; 2018 Jul; 24(7):939-946. PubMed ID: 29892062
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-Mediated Mutagenesis of Human Pluripotent Stem Cells in Defined Xeno-Free E8 Medium.
Soh CL; Huangfu D
Methods Mol Biol; 2017; 1498():57-78. PubMed ID: 27709569
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-based Targeted Genome Editing for the Development of Monogenic Diseases Models with Human Pluripotent Stem Cells.
Gupta N; Susa K; Yoda Y; Bonventre JV; Valerius MT; Morizane R
Curr Protoc Stem Cell Biol; 2018 May; 45(1):e50. PubMed ID: 30040245
[TBL] [Abstract][Full Text] [Related]
9. Highly efficient generation of isogenic pluripotent stem cell models using prime editing.
Li H; Busquets O; Verma Y; Syed KM; Kutnowski N; Pangilinan GR; Gilbert LA; Bateup HS; Rio DC; Hockemeyer D; Soldner F
Elife; 2022 Sep; 11():. PubMed ID: 36069759
[TBL] [Abstract][Full Text] [Related]
10. Introducing Large Genomic Deletions in Human Pluripotent Stem Cells Using CRISPR-Cas3.
Hou Z; Hu C; Ke A; Zhang Y
Curr Protoc; 2022 Feb; 2(2):e361. PubMed ID: 35129865
[TBL] [Abstract][Full Text] [Related]
11. Conditional Gene Knockout in Human Cells with Inducible CRISPR/Cas9.
Snijders KE; Cooper JD; Vallier L; Bertero A
Methods Mol Biol; 2019; 1961():185-209. PubMed ID: 30912047
[TBL] [Abstract][Full Text] [Related]
12. RNA-based CRISPR-Mediated Loss-of-Function Mutagenesis in Human Pluripotent Stem Cells.
Leung AW; Broton C; Bogacheva MS; Xiao AZ; Garcia-Castro MI; Lou YR
J Mol Biol; 2020 Jun; 432(13):3956-3964. PubMed ID: 32339532
[TBL] [Abstract][Full Text] [Related]
13. Semi-automated optimized method to isolate CRISPR/Cas9 edited human pluripotent stem cell clones.
Frank E; Cailleret M; Nelep C; Fragner P; Polentes J; Herardot E; El Kassar L; Giraud-Triboult K; Monville C; Ben M'Barek K
Stem Cell Res Ther; 2023 Apr; 14(1):110. PubMed ID: 37106426
[TBL] [Abstract][Full Text] [Related]
14. Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development.
Shi ZD; Soh CL; Zhu Z; Huangfu D
J Vis Exp; 2017 Mar; (121):. PubMed ID: 28287608
[TBL] [Abstract][Full Text] [Related]
15. Developing CRISPR/Cas9-Mediated Fluorescent Reporter Human Pluripotent Stem-Cell Lines for High-Content Screening.
Vojnits K; Nakanishi M; Porras D; Kim Y; Feng Z; Golubeva D; Bhatia M
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458632
[TBL] [Abstract][Full Text] [Related]
16. The iCRISPR platform for rapid genome editing in human pluripotent stem cells.
Zhu Z; González F; Huangfu D
Methods Enzymol; 2014; 546():215-50. PubMed ID: 25398343
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and rational design of guide RNAs for efficient CRISPR/Cas9-mediated mutagenesis in Ciona.
Gandhi S; Haeussler M; Razy-Krajka F; Christiaen L; Stolfi A
Dev Biol; 2017 May; 425(1):8-20. PubMed ID: 28341547
[TBL] [Abstract][Full Text] [Related]
18. A Robust Protocol for CRISPR-Cas9 Gene Editing in Human Suspension Cell Lines.
Wardyn JD; Chan ASY; Jeyasekharan AD
Curr Protoc; 2021 Nov; 1(11):e286. PubMed ID: 34748280
[TBL] [Abstract][Full Text] [Related]
19. Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination.
Martin RM; Ikeda K; Cromer MK; Uchida N; Nishimura T; Romano R; Tong AJ; Lemgart VT; Camarena J; Pavel-Dinu M; Sindhu C; Wiebking V; Vaidyanathan S; Dever DP; Bak RO; Laustsen A; Lesch BJ; Jakobsen MR; Sebastiano V; Nakauchi H; Porteus MH
Cell Stem Cell; 2019 May; 24(5):821-828.e5. PubMed ID: 31051134
[TBL] [Abstract][Full Text] [Related]
20. [Efficient genome editing in human pluripotent stem cells through CRISPR/Cas9].
Liu GG; Li S; Wei YD; Zhang YX; Ding QR
Yi Chuan; 2015 Nov; 37(11):1167-73. PubMed ID: 26582531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
